These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 35757746)

  • 1. The Past, Present, and Future of Non-Viral CAR T Cells.
    Moretti A; Ponzo M; Nicolette CA; Tcherepanova IY; Biondi A; Magnani CF
    Front Immunol; 2022; 13():867013. PubMed ID: 35757746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering strategies to safely drive CAR T-cells into the future.
    Rossi M; Breman E
    Front Immunol; 2024; 15():1411393. PubMed ID: 38962002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies.
    Yagyu S; Nakazawa Y
    Int J Clin Oncol; 2023 Jun; 28(6):736-747. PubMed ID: 36859566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.
    Hudecek M; Gogishvili T; Monjezi R; Wegner J; Shankar R; Kruesemann C; Miskey C; Ivics Z; Schmeer M; Schleef M
    Recent Results Cancer Res; 2016; 209():37-50. PubMed ID: 28101686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
    Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
    Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
    Irving M; Lanitis E; Migliorini D; Ivics Z; Guedan S
    Hum Gene Ther; 2021 Oct; 32(19-20):1044-1058. PubMed ID: 34662233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.
    Jung IY; Lee J
    Mol Cells; 2018 Aug; 41(8):717-723. PubMed ID: 30110720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of CAR-T Cells with Sleeping Beauty Transposon Gene Transfer.
    Prommersberger S; Monjezi R; Botezatu L; Miskey C; Amberger M; Mestermann K; Hudecek M; Ivics Z
    Methods Mol Biol; 2022; 2521():41-66. PubMed ID: 35732992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
    Ghaffari S; Khalili N; Rezaei N
    J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
    Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
    Singh H; Srour SA; Milton DR; McCarty J; Dai C; Gaballa MR; Ammari M; Olivares S; Huls H; De Groot E; Marin D; Petropoulos D; Olson AL; Anderlini P; Im JS; Khouri I; Hosing CM; Rezvani K; Champlin RE; Shpall EJ; Cooper LJN; Kebriaei P
    Front Immunol; 2022; 13():1032397. PubMed ID: 36439104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy.
    Mirzaei HR; Pourghadamyari H; Rahmati M; Mohammadi A; Nahand JS; Rezaei A; Mirzaei H; Hadjati J
    Cancer Lett; 2018 Jun; 423():95-104. PubMed ID: 29544719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.